Sell the line before the patent breaks. That’s the uncomfortable truth many pharma equipment suppliers learn the hard way: by the time a patent cliff hits, the buying decisions are already made—and the production lines are already booked.
In solid dose…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Drug Patents—What It Means for Innovation and Prices
A lot of people talk about “patents” like they’re all the same. But in the pharmaceutical world, the difference between a standard patent an…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
The hardest part of biologics isn’t making the product. It’s timing the business.
Every biologic loss-of-exclusivity (LOE) creates a predi…

Pharma’s “patent squeeze” isn’t a myth—it’s a strategy.
For years, the public conversation around drug pricing has focused on one moment: when a blockbuster patent expires and generics rush in. But the real story is more tactical—and more continuous….

Patients aren’t asking “about patents.” They’re asking, “Will I be able to get my medicine?”
If you’ve spent any time reading what people search online, you’ll notice something telling: the questions rarely start with legal jargon. They start with life…

Evergreen strategies aren’t new—but the playbook is getting faster, smarter, and harder to spot.
For pharma leaders, the real risk isn’t that a brand files another patent. It’s that the company behind the brand has already mapped the battlefield: which…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Really Changes
The life sciences industry loves a good “breakthrough” story. But the real question isn’t whether AI can generate text, summarize papers, or even draft candi…

Patent cliffs don’t just hit revenue—they reshape the entire payer conversation.
If you’re waiting until a drug’s exclusivity is already expiring to think about “what happens next,” you’re already late. The next phase of competition is rarely decided…

OpenAI’s GPT just did something that sounds like science fiction—but the market impact is very real: it “smashed” drug patent cliffs and reportedly accelerated the discovery of new drug candidates by as much as 70%. That’s the headline. The deeper stor…